Cancer
Malignant Ovarian Neoplasm
CI-CAN-00003205Explore in graph →
Top-level684 active trials5 approved drugs83 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00003205Explore in graph →
Clinical trials
3,086 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (437)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03784378 | Continued Access to RXDX-105 | completed | Phase 1 | 3 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT02632448 | A Study of LY2880070 in Participants With Advanced or Metastatic Cancer | completed | Phase 1 / Phase 2 | 229 | Esperas Pharma Inc.OTHER | 4 | May 2, 2025 | clinicaltrials |
| NCT03054298 |
| CAR T Cells in Mesothelin Expressing Cancers |
| completed |
| Phase 1 |
| 65 |
| University of PennsylvaniaOTHER |
| 1 |
| Apr 29, 2025 |
| clinicaltrials |
| NCT00516724 | Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel | completed | Phase 1 | 189 | AstraZenecaINDUSTRY | 3 | Apr 11, 2025 | clinicaltrials |
| NCT00436254 | Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer | completed | Phase 1 | 66 | University of WashingtonOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT04925284 | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) | completed | Phase 1 | 269 | ExelixisINDUSTRY | 9 | Apr 4, 2025 | clinicaltrials |
| NCT00638898 | Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor | completed | Phase 1 | 25 | City of Hope Medical CenterOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT03206047 | Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 / Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Mar 13, 2025 | clinicaltrials |
| NCT01220154 | Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer | completed | Phase 1 | 9 | David O'MalleyOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT03552471 | Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer | completed | Phase 1 | 25 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT04805333 | Phase 1 Dose Escalation of ArtemiCoffee | completed | Phase 1 | 13 | Frederick R. Ueland, M.D.OTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT04406623 | Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer | completed | Phase 1 | 27 | Shattuck Labs, Inc.INDUSTRY | 1 | Jan 30, 2025 | clinicaltrials |
| NCT04703920 | Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer | completed | Phase 1 | 26 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT03667716 | COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. | completed | Phase 1 | 121 | Compugen LtdINDUSTRY | 1 | Jan 17, 2025 | clinicaltrials |
| NCT05904730 | Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations | completed | Phase 1 | 10 | Lynkcell EuropeOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT04731467 | A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 79 | Famewave Ltd.INDUSTRY | 3 | Dec 27, 2024 | clinicaltrials |
| NCT03997968 | A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 169 | Cyteir Therapeutics, Inc.INDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT02054351 | Phase 1 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR)(OVAR) | completed | Phase 1 | 42 | Ganymed Pharmaceuticals GmbHINDUSTRY | 2 | Nov 21, 2024 | clinicaltrials |
| NCT00889382 | A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors) | completed | Phase 1 / Phase 2 | 152 | Astellas Pharma IncINDUSTRY | 10 | Nov 20, 2024 | clinicaltrials |
| NCT03225989 | Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer | completed | Phase 1 / Phase 2 | 47 | Lokon Pharma ABINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT03761914 | Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers | completed | Phase 1 / Phase 2 | 26 | Sellas Life Sciences GroupINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT00170625 | Therapy With Topotecan and Carboplatin by Patients With Relapsed Ovarian Cancer | completed | Phase 1 / Phase 2 | 28 | North Eastern German Society of Gynaecological OncologyOTHER | 0 | Nov 12, 2024 | clinicaltrials |
| NCT03318900 | T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer | completed | Phase 1 / Phase 2 | 5 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT03246074 | Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer | completed | Phase 1 | 35 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 24, 2024 | clinicaltrials |
| NCT03345485 | Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.(EDO-S101) | completed | Phase 1 / Phase 2 | 71 | Mundipharma Research LimitedINDUSTRY | 5 | Oct 21, 2024 | clinicaltrials |
| NCT03596281 | Pembrolizumab in Combination with Bevacizumab and Pegylated Liposomal Doxorubicin in Patients with Ovarian Cancer(PEMBOV) | completed | Phase 1 | 47 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Oct 18, 2024 | clinicaltrials |
| NCT02480374 | Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer | completed | Phase 1 | 18 | ImunonINDUSTRY | 1 | Oct 2, 2024 | clinicaltrials |
| NCT05002868 | Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors | completed | Phase 1 | 23 | Rhizen Pharmaceuticals SAINDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT05700669 | Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors | completed | Phase 1 / Phase 2 | 3 | Valerio TherapeuticsINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT01606241 | Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 1 | 24 | Mayo ClinicOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT03539406 | Intraperitoneal Infusion of ex Vivo-cultured Allogeneic NK Cells in Recurrent Ovarian Carcinoma Patients(INTRO) | completed | Phase 1 | 11 | Radboud University Medical CenterOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT03206177 | Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary | completed | Phase 1 | 26 | University of OklahomaOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT03154281 | Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast | completed | Phase 1 | 14 | Avera McKennan Hospital & University Health CenterOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT02020707 | Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers | completed | Phase 1 | 43 | Mayo ClinicOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT06517433 | First-in-Human Dose Escalation Study of XMT-1536 in Cancers Likely to Express NaPi2b | completed | Phase 1 | 62 | Mersana TherapeuticsINDUSTRY | 1 | Jul 24, 2024 | clinicaltrials |
| NCT06517485 | First-in-Human Dose Expansion Study of XMT-1536 in Cancers Likely to Express NaPi2b | completed | Phase 1 | 142 | Mersana TherapeuticsINDUSTRY | 1 | Jul 24, 2024 | clinicaltrials |
| NCT04570839 | COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. | completed | Phase 1 / Phase 2 | 48 | Compugen LtdINDUSTRY | 1 | Jul 18, 2024 | clinicaltrials |
| NCT00194714 | Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab | completed | Phase 1 / Phase 2 | 22 | University of WashingtonOTHER | 1 | Jun 6, 2024 | clinicaltrials |
| NCT03126812 | Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer | completed | Phase 1 / Phase 2 | 33 | The Netherlands Cancer InstituteOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT03629756 | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies | completed | Phase 1 | 48 | Arcus Biosciences, Inc.INDUSTRY | 2 | May 24, 2024 | clinicaltrials |
| NCT03719326 | A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies | completed | Phase 1 | 35 | Arcus Biosciences, Inc.INDUSTRY | 2 | May 24, 2024 | clinicaltrials |
| NCT04823065 | 4FMFES-PET Imaging of Endometrial and Ovarian Cancers | completed | Phase 1 / Phase 2 | 53 | Centre de recherche du Centre hospitalier universitaire de SherbrookeOTHER | 1 | May 13, 2024 | clinicaltrials |
| NCT02312661 | Study of Metformin With Carboplatin/Paclitaxel Chemotherapy in Patients With Advanced Ovarian Cancer(OVMET) | completed | Phase 1 | 15 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT03206645 | Unesbulin in Women With Ovarian Cancer Receiving Neoadjuvant Chemotherapy(PTC-001) | completed | Phase 1 | 27 | University of OklahomaOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT06063343 | Evaluation of Safety, Tolerability, Pharmacokinetics, Food Effect and Interaction With Midazolam in Healthy Volunteers After Oral Single and Multiple Ascending Dosing of KAND145 | completed | Phase 1 | 50 | Novakand Pharma ABINDUSTRY | 1 | Apr 22, 2024 | clinicaltrials |
| NCT03490669 | Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors | completed | Phase 1 | 41 | AstraZenecaINDUSTRY | 3 | Apr 5, 2024 | clinicaltrials |
| NCT02996825 | Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer | completed | Phase 1 | 44 | City of Hope Medical CenterOTHER | 1 | Apr 2, 2024 | clinicaltrials |
Data updated 22 days agoSource updated May 15, 2025source: clinicaltrials